Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: Focus on elderly cancer patients

Supportive Care in Cancer

Volumn 12, Issue 7, 2004, Pages 487-496

  Gridelli, Cesare ^a   Aapro, Matti ^b  

^a S G MOSCATI HOSPITAL   (Italy)

^b CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

5 HT3 receptor antagonists; Drug interactions; Elderly; Granisetron

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DOLASETRON MESILATE; GRANISETRON; HYDRODOLASETRON; IMMUNOSUPPRESSIVE AGENT; LORAZEPAM; METHYLPREDNISOLONE; NEUROLEPTIC AGENT; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; PLACEBO; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TROPISETRON; UNINDEXED DRUG;

AGING; BRADYCARDIA; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DIZZINESS; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG UTILIZATION; GERIATRIC CARE; HEART ARRHYTHMIA; HUMAN; NAUSEA AND VOMITING; PHARMACODYNAMICS; PHARMACOKINETICS; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SUDDEN DEATH; TORSADE DES POINTES; VISUAL IMPAIRMENT;

EID: 3142734317     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-004-0596-3     Document Type: Review

References (86)

1. Aapro MS (1993) Methodological issues in antiemetic studies. Invest New Drugs 11:243-253
2. Aapro M, Bourke J (2003) Rapid intravenous administration of granisetron prior to chemotherapy is not arrhythmogenic: results of a pilot study. Eur J Cancer 39:927-931
3. Addelman M, Erlichman C, Fine S, Warr D, Murray C (1990) Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 8:337-341
4. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J (1995) Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274:626-631
5. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156:127-132
6. Algra A, Tijssen JGP, Roelandt JRTC, Pool J, Lubsen J (1991) QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 83:1888-1894
7. Anonymous (2000) Cytochrome P450. http://www.anaesthetist.com/physiol/ basics/metabol/cyp/cyp.htm
8. Ashanani F, Heys SD, Eremin O (1999) The management of cancer in the elderly. J R Coll Surg Edinb 44:2-10
9. Audhuy B, Cappelaere P, Marin M, et al (1996) A double-blind, randomised comparison of the antiemetic efficacy of two intravenous doses of dolasetron mesylate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 32A:807-813
10. Aventis Pharmaceuticals (2000) Anzemet (dolasetron mesylate). Prescribing information
11. Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258
12. Bloomer JC, Baldwin SJ, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ (1994) Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 38:557-566
13. 3 receptor antagonism in the control of cytostatic drug-induced emesis. Eur J Cancer 26 [Suppl 1]:S8-11
14. Blum RA, Majumdar A, McCrea J, et al (2003) Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 25:1407-1419
15. Boike SC, Ilson B, Zariffa N, Jorkasky DK (1997) Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 54:1172-1176
16. Boxenbaum H, Gillespie T, Heck K, Hahne W (1992) Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 13:693-701
17. Cagnoni PJ, Matthes S, Day TC, Bearman SI, Shpall EJ, Jones RB (1999) Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 24:1-4
18. Carmichael J, Bergstrom B (2002) The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy (abstract). 14th International Symposium of the Multinational Association of Supportive Care in Cancer (MASCC), 23-26 June 2002, Boston, MA
19. 3 receptor antagonist: correlation with antiemetic response. Cancer Chemother Pharmacol 24:45-49
20. Carmichael J, Philip PA, Forfar C, Harris AL (1995) An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemother Pharmacol 37:134-138
21. Catterson ML, Preskom SH, Martin RL (1997) Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Geriatr Psychiatry 20:205-218
22. Coeburgh JWW (1996) Significant trends in cancer in the elderly. Eur J Cancer 32A:569-571
23. Cowan JD, Neidhart J, McClure S, et al (1991) Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst 83:1077-1084
24. Danjoux CE, Rider WD, Fitzpatrick PJ (1979) The acute radiation syndrome. A memorial to William Michael Court-Brown. Clin Radiol 30:581-588
25. Davis MP, Homsi J (2001) The importance of cytochrome P450 monooxygenase CYP2D6 in palliative care. Support Care Cancer 9:442-451
26. Dixon CM, Colthup PV, Serabjit-Singh CJ, et al (1995) Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 23:1225-1230
27. Doherty KM (1999) Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 3:113-119
28. Dretakis KE, Dretakis EK, Papakitsou EF, Psarakis S, Steriopoulos K (1998) Possible predisposing factors for the second hip fracture. Calcif Tissue Int 62:366-369
29. Eastell R, Reid DM, Compston J, et al (2001) Secondary prevention of osteoporosis-when should a non-vertebral fracture be a trigger for action? Q J Med 94:575-597
30. Ewer MS, Benjamin RS (1997) Cardiac complications. In: Holland JF, Bast RC, Morton DL, et al (eds) Cancer medicine, 4th edn. Williams and Wilkins, Baltimore, pp 3197-215
31. Extermann M (2002) Comorbidity and geriatric assessment in the elderly patient over the age of 70. Tumori 88 [Suppl 1]:S9
32. Extermann M, Aapro M (2000) Assessment of the older cancer patient. Hematol Oncol Clin North Am 14:63-77
33. Faulds D, Balfour JA, Chrisp P, Langtry HD (1991) Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 41:400-449
34. FDA (2003) Background information regarding EMEND(tm) (aprepitant) capsules. Gastrointestinal Drugs Advisory Committee, 6 March 2003, briefing Information. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3928b1.htm
35. 3 receptor mediate cisplatin-induced emesis in dogs (abstract). Jpn J Pharmacol 55 [Suppl 1]:152P
36. Gaedigk A (2000) Interethnic differences of drug-metabolizing enzymes. Int J Clin Pharmacol Ther 38:61-68
37. Gilbert CJ, Petros WP, Vredenburgh J, et al (1998) Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 42:497-503
38. GlaxoSmithKline (1999) Zofran (ondansetron hydrochloride) tablets and Injection. Prescribing information
39. Gralla RJ, Osoba D, Kris MG, et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971-2994
40. Gridelli C, Perrone F, Gallo C, et al (2003) Chemotherapy for elderly patients with advanced non small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study phase III randomized trial. J Natl Cancer Inst 95:362-372
41. Hesketh P, Navari R, Grote T, et al (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 14:2242-2249
42. 3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 97:247-255
43. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS (1999) Underrepresentation of patients aged 65 years or older in cancer-treatment trials. N Engl J Med 341:2061-2067
44. Italian Group for Antiemetic Research (1995) Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6:805-810
45. Jörgensen T, Johansson S, Kennerfalk A, Wallander M-A, Svärdsudd K. (2001) Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 35:1004-1009
46. Kaiser R, Sezer O, Papies A, et al (2002) Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805-2811
47. Keefe DL (2000) Cardiovascular emergencies in the cancer patient. Semin Oncol 27:244-255
48. 3 receptor antagonist antiemetics: is there cause for concern? Oncologist 7:65-72
49. Kees F, Färber L, Bucher M, Mair G, Mörike K, Grobecker H (2001) Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Br J Clin Pharmacol 52:705-707
50. Kleisbauer J-P, García-Girón C, Antimi M, Azevedo MC, Blames H, Massuti-Sureda B, Contu A, Luque A, Pellier P (1998) Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis. Anticancer Drugs 9:387-332
51. Koriech OM (1995) Fluoxetine treatment compromises the antiemetic efficacy of ondansetron in cancer patients. Clin Oncol 7:371-372
52. Kris MG, Cubeddu LX, Gralla RJ, et al (1996) Are more antiemetic trials with placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer 78:2193-2198
53. Laszlo J (1983) Emesis as limiting toxicity in cancer chemotherapy. In: Laszlo J (ed) Antiemetics and cancer chemotherapy. Williams and Wilkins, Baltimore London, pp 1-5
54. Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS, Osterhaus JT (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331-340
55. Lorenz C, Eickhoff C, Bauman F, et al (2000) Does ondansetron affect the metabolism of cyclophosphamide? Int J Clin Pharmacol Ther 38:143-144
56. Love RR, Leventhal H, Easterling DV, Nerenz DR (1989) Side effects and emotional distress during cancer chemotherapy. Cancer 63:604-612
57. Lowenthal RM, Eaton K (1996) Toxicity of chemotherapy. Hematol Oncol Clin North Am 10:967-990
58. Marez D, Legrand M, Sabbagh N, et al (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 56 alleles, their frequencies and evolution. Pharmacogenetics 7:193-202
59. Merck (2003) Emend, prescribing information. Merck and Company, Whitehouse Station, NJ
60. 3 receptor antagonists in patients at risk of QTc prolongation: results of a retrospective claims based analysis (abstract P-364D). 37th American Society of Health System Pharmacists, 8-12 December, Atlanta, GA
61. 3-receptor antagonists. Br J Clin Pharmacol 37:525-530
62. Monfardini S, Sorio R, Boes GH, Kaye S, Serraino D (1995) Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies. Cancer 76:333-338
63. 3 binding sites in rat brain cortical membranes. Biochem Pharmacol 38:1693-1695
64. 3 receptors. Neuropharmacology 32:729-735
65. Novartis Pharmaceuticals (1997) Navoban (tropisetron). Product information
66. O'Brien BJ, Rusthoven J, Rocchi A, Latreille J, Fine S, Vandenberg T, Laberge F (1993) Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. Can Med Assoc J 149:296-302
67. Perez EA, Hesketh P, Sandbach J, et al (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16:754-760
68. Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C (1998) Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 4:52-58
69. Pignon J-P, Arriagada R, Ihde DC, et al (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618-1624
70. Ramamoorthy Y, Suh N, Tyndale RF, Sellers EM (2000) Differentially altered metabolism and inhibition of CYP2D6*10 (abstract). Clin Pharmacol Ther 67:121
71. Roche Laboratories (2000) Kytril (granisetron hydrochloride) tablets and injection. Prescribing information
72. Roila F, Del Favero A (1995) Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 29:95-109
73. Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332:1004-1014
74. Ruff P, Paska W, Goedhals L, et al (1994) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 51:113-118
75. 3 antagonists. Drug Metab Dispos 24:602-609
76. Satariano WA (1993) Aging, comorbidity, and breast cancer survival: an epidemiologic view. Adv Exp Med Biol 330:1-11
77. Seidman A, Hudis C, Pierri MK, et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221
78. Shah A, Lanman R, Bhargava V, Weir S, Hahne W (1995) Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 16:177-189
79. Sheehy CM, Perry PA, Cromwell SL (1999) Dehydration: biological considerations, age-related changes, and risk factors in older adults. Biol Res Nurs 1:30-37
80. Sparano JA (2002) Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol 28 [Suppl 3]:20-27
81. Stanford BJ, Stanford SC (1999) Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psychopharmacol 13:313-317
82. 3 antagonist. Eur J Cancer 26 [Suppl 1]:S12-S15
83. Van Wijngaarden I, Tulp MTM, Soudijn W (1990) The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 188:301-312
84. Wei JY (1995) Cardiovascular comorbidity in the older cancer patient. Semin Oncol 22 [Suppl 1]:9-10
85. Yancik R (1997) Cancer burden in the aged. An epidemiologic and demographic overview. Cancer 80:1273-1283
86. Yancik R, Ries LAG (2000) Aging and cancer in America. Hematol Oncol Clin North Am 14:17-23